ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1556

Latent Profiles of Parenchymal Abnormalities and Vascular Features Measured by Quantitative CT Identifies a Subgroup of Systemic Sclerosis Patients With a Greater Lung Function Decline Over Time

Alicia Hinze1, Nishanth Katurkuri2, Robert Vassallo2, Ami Shah3, Ryan Lennon2, Brian Bartholmai2 and Cynthia Crowson4, 1Mayo Clinic - Rochester, MN, Rochester, MN, 2Mayo Clinic, Rochester, MN, 3Johns Hopkins Rheumatology, Baltimore, MD, 4Mayo Clinic, Stewartvillle, MN

Meeting: ACR Convergence 2025

Keywords: Cohort Study, Computed tomography (CT), interstitial lung disease, Systemic sclerosis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, October 27, 2025

Title: (1553–1591) Systemic Sclerosis & Related Disorders – Clinical Poster II

Session Type: Poster Session B

Session Time: 10:30AM-12:30PM

Background/Purpose: The clinical course of interstitial lung disease (ILD) in systemic sclerosis (SSc) is highly variable–some patients experience progressive loss of lung function while others remain stable. Although risk factors such as early disease, diffuse cutaneous subtype, Black race, and >20% ILD on baseline CT increase the likelihood of progression, ILD progression can also occur in their absence. This study aimed to develop radiomic profiles linked to pulmonary function decline by analyzing quantitative CT measures of lung parenchymal and vascular abnormalities in early SSc.

Methods: A retrospective cohort of adult (≥18 yrs) patients with systemic sclerosis (SSc) seen at an academic center (1/1/2007–12/31/2018) was identified using ICD-9/10 codes. Records were reviewed, and patients included if they met ACR/EULAR 2013 SSc classification criteria or ≥3/5 CREST criteria and had ILD. Inclusion required a baseline high-resolution CT (HRCT) ±2 yrs of SSc diagnosis and a PFT ±6 mo. of HRCT. Patients with infection, pleural effusion, cardiogenic edema, or non-SSc ILD were excluded. CALIPER software quantified six lung features (normal, ground glass opacities (GGO), reticular densities (RD), honeycombing (HC), hyperlucency, and pulmonary vascular related structures (PVRS)) by lung zone (upper/middle/lower, central/peripheral). Each feature was expressed as a % of lung volume for that zone. Percent predicted forced vital capacity (ppFVC) was standardized using the GLI 2022 equations.1 Latent Profile Analysis (LPA) identified radiomic clusters from CALIPER measurements. Mixed effects models estimated annual ppFVC decline by cluster, adjusting for baseline ppFVC, including linear and quadratic effects for the change over time.

Results: Of 1,399 SSc patients identified, 712 had ILD, 315 had a CT ±2 yrs of SSc diagnosis, and 116 met inclusion criteria with ≥1 follow-up PFT. LPA identified two radiomic profiles (LP1 & LP2). LP1 had lower percentages of ILD, GGO, RD, HC, and PVRS (Table 1). There were no significant differences in demographics, smoking history, SSc dx. dur., subtype or other clinical features, anti-Scl70, or anti-centromere Abs (Table 1). RNA Pol III was less frequent in LP1 than LP2 (18% vs. 46%, p=0.048). LP1 had a shorter interval from ILD dx. to HRCT (median 0.0 vs. 0.5 yrs; p< 0.001), and better lung function at baseline (median ppFVC (85% vs. 75%) and ppDLCO (64% vs. 49%), both p< 0.001). In longitudinal analysis, LP2 had a faster rate of ppFVC decline: -2.66% per year (95% CI: –4.65 to –0.67; p=0.011) relative to LP1, adjusting for baseline ppFVC (Table 2, Model 1). This association was slightly attenuated after adjusting for age, sex, ILD dur., Scl-70(+), and diffuse subtype (–2.18% per year; 95% CI: –4.35 to 0.01; p=0.054; Table 2, Model 2; Fig 1).

Conclusion: Two early SSc-ILD radiomic phenotypes were identified. Frequencies of clinical risk factors for ILD progression were similar between profiles. One radiomic profile was associated with greater parenchymal and vascular abnormalities and faster lung function decline. Imaging-based phenotyping using radiomic biomarkers may enhance risk stratification and identify patients at higher risk for ILD progression. Ref. 1. Bowerman, C. et. Al., AJRCCM, 2022.

Supporting image 1Table 1. Baseline Demographics, Clinical Characteristics, Pulmonary Function Studies (PFTs), and Quantitative CT Values with Comparison Between Latent Profile 1 (LP1) and Latent Profile 2 (LP2)

Supporting image 2Table 2. Estimated Difference in the Change in ppFVC per year for Latent Profile 2 Compared to Latent Profile 1

Supporting image 3Figure 1. Difference in the Estimated Rate of Decline in percent predicted FVC (ppFVC) per year for Latent Profile (LP) 1 vs. LP 2, adjusting for age, sex, baseline ppFVC, ILD duration, diffuse cutaneous disease, and a positive Scl70


Disclosures: A. Hinze: None; N. Katurkuri: None; R. Vassallo: Regeneron, 6, Rion LLC, 11, Sanofi, 2; A. Shah: None; R. Lennon: None; B. Bartholmai: None; C. Crowson: None.

To cite this abstract in AMA style:

Hinze A, Katurkuri N, Vassallo R, Shah A, Lennon R, Bartholmai B, Crowson C. Latent Profiles of Parenchymal Abnormalities and Vascular Features Measured by Quantitative CT Identifies a Subgroup of Systemic Sclerosis Patients With a Greater Lung Function Decline Over Time [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/latent-profiles-of-parenchymal-abnormalities-and-vascular-features-measured-by-quantitative-ct-identifies-a-subgroup-of-systemic-sclerosis-patients-with-a-greater-lung-function-decline-over-time/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/latent-profiles-of-parenchymal-abnormalities-and-vascular-features-measured-by-quantitative-ct-identifies-a-subgroup-of-systemic-sclerosis-patients-with-a-greater-lung-function-decline-over-time/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology